PAs May Have Lower Diagnostic Accuracy for Melanoma

Share this content:
PAs May Have Lower Diagnostic Accuracy for Melanoma
PAs May Have Lower Diagnostic Accuracy for Melanoma

FRIDAY, April 20, 2018 (HealthDay News) -- Physician assistants (PAs) perform more skin biopsies per case of skin cancer diagnosed and diagnose fewer melanomas in situ than dermatologists, according to a study published online April 18 in JAMA Dermatology.

Alyce M. Anderson, Ph.D., from the University of Pittsburgh School of Medicine, and colleagues compared the diagnostic accuracy for skin cancer of PAs with that of dermatologists. Medical records were reviewed for 33,647 skin cancer screening examinations in 20,270 unique patients.

The researchers found that the number needed to biopsy (NNB) to diagnose one case of skin cancer was 3.9 for PAs and 3.3 for dermatologists (P < 0.001). Per diagnosed melanoma, the NNB was 39.4 and 25.4 for PAs and dermatologists, respectively (P = 0.007). Compared with those screened by a dermatologist, patients screened by a PA were significantly less likely to be diagnosed with melanoma in situ (1.1 versus 1.8 percent of visits; P = 0.02); for invasive melanoma (0.7 versus 0.8 percent of visits; P = 0.83) and nonmelanoma skin cancer (6.1 versus 6.1 percent of visits; P = 0.98), the differences were not significant.

"Although the availability of PAs may help increase access to care and reduce waiting times for appointments, these findings have important implications for the training, appropriate scope of practice, and supervision of PAs and other nonphysician practitioners in dermatology," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »